OBJECTIVE: Hypoglycemia is associated with increased mortality. The reasons for this remain unclear, and the effects of low glucose exposure on vascular endothelial function remain largely unknown. We endeavored to determine the effects of low glucose on endothelial cells and intact human arterioles. METHODS AND RESULTS: We exposed human umbilical vein endothelial cells to low glucose conditions in a clinically relevant range (40-70 mg/dL) and found rapid and marked reductions in nitric oxide (NO) bioavailability (P<0.001). This was associated with concomitantly increased mitochondrial superoxide production (P<0.001) and NO-dependent mitochondrial hyperpolarization (P<0.001). Reduced NO bioavailability was rapid and attributable to reduced endothelial nitric oxide synthase activity and destruction of NO. Low glucose rapidly activated AMP kinase, but physiological activation failed to restore NO bioavailability. Pharmacological AMP kinase activation led to phosphorylation of endothelial nitric oxide synthase's Ser633 activation site, reversing the adverse effects of low glucose. This protective effect was prevented by L-NG-Nitroarginine methyl ester. Intact human arterioles exposed to low glucose demonstrated marked endothelial dysfunction, which was prevented by either metformin or TEMPOL. CONCLUSION: Our data suggest that moderate low glucose exposure rapidly impairs NO bioavailability and endothelial function in the human endothelium and that pharmacological AMP kinase activation inhibit this effect in an NO-dependent manner.
OBJECTIVE:Hypoglycemia is associated with increased mortality. The reasons for this remain unclear, and the effects of low glucose exposure on vascular endothelial function remain largely unknown. We endeavored to determine the effects of low glucose on endothelial cells and intact human arterioles. METHODS AND RESULTS: We exposed human umbilical vein endothelial cells to low glucose conditions in a clinically relevant range (40-70 mg/dL) and found rapid and marked reductions in nitric oxide (NO) bioavailability (P<0.001). This was associated with concomitantly increased mitochondrial superoxide production (P<0.001) and NO-dependent mitochondrial hyperpolarization (P<0.001). Reduced NO bioavailability was rapid and attributable to reduced endothelial nitric oxide synthase activity and destruction of NO. Low glucose rapidly activated AMP kinase, but physiological activation failed to restore NO bioavailability. Pharmacological AMP kinase activation led to phosphorylation of endothelial nitric oxide synthase's Ser633 activation site, reversing the adverse effects of low glucose. This protective effect was prevented by L-NG-Nitroarginine methyl ester. Intact human arterioles exposed to low glucose demonstrated marked endothelial dysfunction, which was prevented by either metformin or TEMPOL. CONCLUSION: Our data suggest that moderate low glucose exposure rapidly impairs NO bioavailability and endothelial function in the human endothelium and that pharmacological AMP kinase activation inhibit this effect in an NO-dependent manner.
Authors: Mildred M Pelletier; Petra Kleinbongard; Lorna Ringwood; Rania Hito; Christian J Hunter; Alan N Schechter; Mark T Gladwin; André Dejam Journal: Free Radic Biol Med Date: 2006-05-10 Impact factor: 7.376
Authors: Brian D Fink; Krzysztof J Reszka; Judy A Herlein; Mary M Mathahs; William I Sivitz Journal: Am J Physiol Endocrinol Metab Date: 2004-08-31 Impact factor: 4.310
Authors: Tun Nyunt; Monica Britton; Kwanjeera Wanichthanarak; Madhu Budamagunta; John C Voss; Dennis W Wilson; John C Rutledge; Hnin H Aung Journal: Free Radic Biol Med Date: 2019-07-26 Impact factor: 7.376
Authors: Mobin Malik; Tisha M Suboc; Sudhi Tyagi; Nita Salzman; Jingli Wang; Rong Ying; Michael J Tanner; Mamatha Kakarla; John E Baker; Michael E Widlansky Journal: Circ Res Date: 2018-10-12 Impact factor: 17.367
Authors: Nino G Joy; Jennifer M Perkins; Maia Mikeladze; Lisa Younk; Donna B Tate; Stephen N Davis Journal: J Diabetes Complications Date: 2016-07-04 Impact factor: 2.852